Exelixis, Inc. Looks Ahead -- but the 3rd Quarter Wasn't Too Shabby
Exelixis (NASDAQ: EXEL), the biotech once left for dead by quite a few investors, continues its resurgence with another solid quarter of sales of its kidney cancer drug Cabometyx. Of course, the third quarter almost doesn't matter that much since most of the biotech's current valuation is supported by potential future sales as Exelixis hopes to expand drug treatment of first-line kidney cancer as well as liver cancer.
Metric
Q3 2017
Source: Fool.com
Exelixis Inc. Aktie
21,52 €
0,89 %
Absolute Beliebtheit: Exelixis Inc. hat nur Buy-Einschätzungen.
Das Kursziel von 26 € für Exelixis Inc. bedeutet eine deutliche Steigerung von über 20% gegenüber dem aktuellen Kurs von 21.52 €.
